---
title: "Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688553.SH.md"
symbol: "688553.SH"
name: "Sichuan Huiyu Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T15:35:18.351Z"
locales:
  - [en](https://longbridge.com/en/quote/688553.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688553.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688553.SH.md)
---

# Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SH)

## Company Overview

Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone drugs. It also offers moroxydine sodium chloride, fluorouracil, sodium thiosulfate, acetylcysteine, nimodipine, nimodipine, dihydroxypropyltheophylline, cisatracurium besylate, cladribine, sodium carbosulfan, octreotide acetate, mesobamo, doxorubicin, leucovorin calcium, panosetron hydrochloride, famotidine, etoposide, polymyxin B sulfate, melphalan hydrochloride, thiotepa, teicoplanin, epirubicin hydrochloride, methotrexate, gemcitabine hydrochloride, cytarabine, voriconazole, roxatidine acetate hydrochloride, and bortezomib drugs.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.huiyupharma.com](https://www.huiyupharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.53)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 109 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -5.73% |  |
| Net Profit YoY | -91.10% |  |
| P/B Ratio | 2.25 |  |
| Dividend Ratio | 2.30% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8508286866.10 |  |
| Revenue | 1030128049.12 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.58% | D |
| Profit Margin | 2.19% | C |
| Gross Margin | 79.18% | A |
| Revenue YoY | -5.73% | D |
| Net Profit YoY | -91.10% | E |
| Total Assets YoY | 3.62% | C |
| Net Assets YoY | -4.48% | D |
| Cash Flow Margin | 479.80% | A |
| OCF YoY | -5.73% | D |
| Turnover | 0.20 | D |
| Gearing Ratio | 26.50% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sichuan Huiyu Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-5.73%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-91.10%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.25",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.30%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8508286866.10",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1030128049.12",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.58%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "2.19%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "79.18%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-5.73%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-91.10%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.62%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-4.48%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "479.80%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-5.73%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.20",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "26.50%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 394.01 | 161/215 | 182.59 | 159.10 | 37.44 |
| PB | 2.35 | 110/215 | 2.50 | 2.26 | 2.03 |
| PS (TTM) | 8.63 | 170/215 | 9.07 | 8.37 | 7.66 |
| Dividend Yield | 2.20% | 59/215 | 2.47% | 2.26% | 2.02% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688553.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688553.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688553.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**